These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30853815)

  • 41. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
    Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
    Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Economic evaluation in oncology].
    Schöffski O
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():14-7. PubMed ID: 10941248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A deliberative framework to identify the need for real-life evidence building of new cancer drugs after interim funding decision.
    Leung L; de Lemos ML; Kovacic L
    J Oncol Pharm Pract; 2018 Dec; 24(8):584-598. PubMed ID: 28747103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
    Masucci L; Beca J; Sabharwal M; Hoch JS
    Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials.
    Lasala R; Logreco A; Romagnoli A; Santoleri F; Musicco F; Costantini A
    Eur J Clin Pharmacol; 2020 Jun; 76(6):843-850. PubMed ID: 32125472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
    Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
    Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
    [No Abstract]   [Full Text] [Related]  

  • 47. Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis.
    Graili P
    Appl Health Econ Health Policy; 2023 Jul; 21(4):673-681. PubMed ID: 36609982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.
    Jenei K; Peacock S; Burgess M; Mitton C
    Curr Oncol; 2021 Jul; 28(4):2708-2719. PubMed ID: 34287280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration.
    Ezeife DA; Truong TH; Heng DY; Bourque S; Welch SA; Tang PA
    Cancer; 2015 May; 121(10):1688-93. PubMed ID: 25604014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy.
    Bentley C; Peacock S; Abelson J; Burgess MM; Demers-Payette O; Longstaff H; Tripp L; Lavis JN; Wilson MG
    Health Res Policy Syst; 2019 Feb; 17(1):17. PubMed ID: 30732616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The reality of economics for oncologists.
    Taylor D
    Breast; 2017 Jun; 33():183-190. PubMed ID: 28432979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholders.
    Wranik WD; Skedgel C; Hu M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):59-69. PubMed ID: 30169973
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea.
    Bae G; Bae EY; Bae S
    Health Policy; 2015 May; 119(5):577-87. PubMed ID: 25666339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Canadian status of "drugs to avoid" in 2017: a descriptive analysis.
    Lexchin J
    CMAJ Open; 2018; 6(3):E430-E435. PubMed ID: 30266781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
    Daroudi R; Mirzania M; Zendehdel K
    Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
    Jackson EB; Hotte SJ
    Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.